Latest Information Update: 19 Nov 2001
At a glance
- Originator Bristol-Myers Squibb
- Class Antifungals
- Mechanism of Action Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 19 Nov 2001 Discontinued-Preclinical for Candidiasis in Japan (Unknown route)
- 07 Nov 1995 Discontinued-Preclinical for Mycoses in Japan (Unknown route)